The latest news round up for trade-able items on the First Global Credit platform, covering:
- Biogen Idec
- Clovis Oncology
- Eli Lilly & Co
- International Business Machines
Amazon.com, Inc (NASDAQ:AMZN)
Amazon.com Inc’s shares reached another record, three days before the company’s earnings report, as investors expected upbeat results from the fast-growing cloud-computing business, a boost in sales from last week’s Prime Day promotion and signs that the company is controlling spending.
Amazon rose 1.1 per cent to close at US$488.10 (RM1,858.20) in New York yesterday. The stock set records three days last week and is up 12 per cent this month, while the Standard & Poor’s 500 Retailing Index has gained 5.5 per cent.
The Seattle-based online retailer reports earnings Thursday. Analysts on average project earnings of US$364 million on sales of US$22.4 billion, according to data compiled by Bloomberg.
Biogen Idec, Inc (NASDAQ:BIIB)
In an analyst note revealed to clients and investors by Goldman Sachs on 20 July, Biogen Idec Inc (NASDAQ:BIIB) had its target upped to $435.00. The firm currently has Neutral rating on the stock.
Biogen Idec Inc. shares have increased 22.32% over the past 200 days, while the Standard & Poor’s 500 index has increased 7.83% during the same time.
The 12-month consensus target price for the stock is $476.38, which reflects an upside potential of 16.64% over the current price.
For more go to: http://www.octafinance.com/biogen-idec-inc-nasdaqbiib-had-its-pt-increases-by-analysts-at-goldman-sachs-to-435-00/108608/
Bitcoin has risen 1.3% or $3.6 since yesterday as bulls finally make an attempt to approach the resistance. This is somewhat encouraging given that the Greek banks were opened yesterday and citizens were allowed to withdraw their Euros. Maybe the market is expecting the Greeks to convert their withdrawn Euros into Bitcoin for capital preservation purposes.
Clovis Oncology (NASDAQ:CLVS)
Goldman Sachs raised shares of Clovis Oncology Inc from “Buy” rating to “Conviction Buy” rating in analysts report issued on 20 July.
The stock rating upgrade is welcomed by equity traders, as Clovis Oncology Inc is right now trading 1.33% higher at $88.22 as of 11:07 New York time. Clovis Oncology Inc’s stock is up 91.93% in the past 200 days. It has outperformed the S&P 500, which has added 7.83% in the same time period.
The 12-month mean target is $107.29, which means upside potential of 21.62% over the current price.
Eli Lilly & Co (NYSE:LLY)
Zacks has upgraded shares of Eli Lilly from a hold rating to a buy rating in a research report released on Monday morning. Zacks currently has $98.00 price objective on the stock.
According to Zacks, “Lilly’s first-quarter earnings were well above expectations. Some of the company’s key products and the animal health business should keep performing well. The company also has some new products in its portfolio which should start contributing to revenues. Lilly is also working on controlling costs and is slated to return to growth from 2015. Share buybacks and cost control should help Lilly achieve its 2015 guidance. We are also pleased to see Lilly pursuing small acquisitions and in-licensing deals to boost its pipeline. However, headwinds remain in the form of the genericization of Cymbalta and Evista and negative currency movement. The company has also had its share of pipeline setbacks.”
International Business Machines (NYSE:IBM)
International Business Machine Corp.’s revenue decline was worse than expected in the second quarter, and shares dove 4% in after-hours trading following the results. The tech giant reported net income of $3.4 billion, or $3.50 a share, on revenue of $20.8 billion; after adjustments, IBM reported profit of $3.84 a share.
IBM was expected to report adjusted earnings of $3.79 a share on sales of $20.9 billion, according to a FactSet survey of analysts. IBM’s revenue was down 13.5% from the same quarter last year, and the company has missed revenue expectations the past four quarters in a row.
For more go to: http://stream.marketwatch.com/story/markets/SS-4-4/SS-4-84304/
Google, Inc (NASDAQ:GOOG)
In an analyst report issued on today, Argus reconfirmed their Buy rating on Google (NASDAQ:GOOG)’s stock. The PT would suggest a potential upside of 28.42% from firm’s current stock price.
NASDAQ:GOOG is now trading -1.64% lower at $661.87 as of 16:02 New York time. Google’s stock is up 16.55% in the last 200 days. It has outperformed the S&P500 Index, which has risen 7.83% in the same time.
The 12-month consensus target price for the stock is $645, which reflects a downside potential of 2.55% over the current price.